Wedbush Upgrades Apellis Pharmaceuticals (APLS) to Neutral
Tweet
Share
E-mailGet Alerts APLS Hot Sheet
Price: $41.03 --0%
Rating Summary:
6 Buy, 23 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 20
Rating Summary:
6 Buy, 23 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 20
Join SI Premium – FREE
Wedbush analyst Laura Chico upgraded Apellis Pharmaceuticals (NASDAQ: APLS) from Underperform to Neutral with a price target of $29.00.
For an analyst ratings summary and ratings history on Apellis Pharmaceuticals click here. For more ratings news on Apellis Pharmaceuticals click here.
Shares of Apellis Pharmaceuticals closed at $30.95 yesterday.
You May Also Be Interested In
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- Maxim Group Upgrades Co-Diagnostics (CODX) to Buy
- BMO Capital Resumes Global Net Lease (GNL), Upgrades to Outperform
Create E-mail Alert Related Categories
UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
